Allarity Therapeutics
ALLR
6 hedge funds and large institutions have $122K invested in Allarity Therapeutics in 2024 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
165% more capital invested
Capital invested by funds: $46.2K → $122K (+$76.1K)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
50% more funds holding
Funds holding: 4 → 6 (+2)
0.81% more ownership
Funds ownership: 1.55% → 2.36% (+0.81%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$89.2K |
| 2 |
Goldman Sachs
New York
|
+$27.3K |
| 3 |
Citigroup
New York
|
+$16.3K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.14K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$15 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$38.9K |
| 2 |
DB
Danske Bank
Copenhagen K,
Denmark
|
-$9 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SCM
1
Stonepine Capital Management
Bend,
Oregon
| $78.7K | +$89.2K | +67,289 | New |
|
|
2
Goldman Sachs
New York
| $24.1K | +$27.3K | +20,616 | New |
|
|
3
Citigroup
New York
| $14.4K | +$16.3K | +12,294 | New |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $4.99K | +$1.14K | +863 | +25% |
|
|
5
Bank of America
Charlotte,
North Carolina
| $26 | +$15 | +11 | +100% |
|
|
DB
6
Danske Bank
Copenhagen K,
Denmark
| $1 | -$9 | -7 | -88% |
|
|
7
UBS Group
Zurich,
Switzerland
| – | -$38.9K | -18,452 | Closed |
|
ALLR Hedge Fund Activity: Q4 2024 in Review
6 of the 7,599 institutional investors tracked by Wall St. Rank reported a position in Allarity Therapeutics (ALLR) for Q4 2024, worth a combined $122K — up 165% from $46.2K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ALLR positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $89.2K. The largest seller was UBS Group, exiting entirely with an estimated $38.9K sold.
- 6 institutional investors held Allarity Therapeutics (ALLR) as of Q4 2024, up from 4 in Q3 2024.
- Funds reported $122K of Allarity Therapeutics stock for Q4 2024, up 165% quarter-over-quarter.
- 3 funds opened new Allarity Therapeutics positions in Q4 2024 and 1 closed out, a net change of +2 holders.
- The largest Allarity Therapeutics buyer in Q4 2024 was Stonepine Capital Management, an estimated $89.2K added.
- The largest Allarity Therapeutics seller in Q4 2024 was UBS Group, an estimated $38.9K sold.
Based on aggregated 13F filings for Q4 2024.